Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Prevention of tuberculosis in household members: estimates of children eligible for treatment.

Hamada Y, Glaziou P, Sismanidis C, Getahun H.

Bull World Health Organ. 2019 Aug 1;97(8):534-547D. doi: 10.2471/BLT.18.218651. Epub 2019 May 28.

2.

Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis.

Assefa Y, Woldeyohannes S, Gelaw YA, Hamada Y, Getahun H.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):728-734. doi: 10.5588/ijtld.18.0547.

PMID:
31315706
3.

Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review.

Hamada Y, Ford N, Schenkel K, Getahun H.

Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1422-1428. doi: 10.5588/ijtld.18.0168.

PMID:
30606313
4.

Identifying priorities for HIV-associated tuberculosis research through the WHO guidelines process.

Ford N, Maher D, Rangaka MX, Baddeley A, Singh S, Getahun H.

Curr Opin HIV AIDS. 2018 Nov;13(6):538-542. doi: 10.1097/COH.0000000000000499. Review.

PMID:
30286042
5.

Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis.

Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H.

Lancet HIV. 2018 Sep;5(9):e515-e523. doi: 10.1016/S2352-3018(18)30137-1. Epub 2018 Aug 20.

PMID:
30139576
6.

Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings.

Denning DW, Page ID, Chakaya J, Jabeen K, Jude CM, Cornet M, Alastruey-Izquierdo A, Bongomin F, Bowyer P, Chakrabarti A, Gago S, Guto J, Hochhegger B, Hoenigl M, Irfan M, Irurhe N, Izumikawa K, Kirenga B, Manduku V, Moazam S, Oladele RO, Richardson MD, Tudela JLR, Rozaliyani A, Salzer HJF, Sawyer R, Simukulwa NF, Skrahina A, Sriruttan C, Setianingrum F, Wilopo BAP, Cole DC, Getahun H.

Emerg Infect Dis. 2018 Aug;24(8). doi: 10.3201/eid2408.171312.

7.

Implementation of tuberculosis prevention for exposed children, Burkina Faso.

Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimbo A, Capone S, Hamada Y, Baddeley A, Matteelli A.

Bull World Health Organ. 2018 Jun 1;96(6):386-392. doi: 10.2471/BLT.17.201343. Epub 2018 Apr 20.

8.

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.

Assefa Y, Assefa Y, Woldeyohannes S, Hamada Y, Getahun H.

Eur Respir J. 2018 Jul 11;52(1). pii: 1800395. doi: 10.1183/13993003.00395-2018. Print 2018 Jul. No abstract available.

9.

National policies on the management of latent tuberculosis infection: review of 98 countries.

Jagger A, Reiter-Karam S, Hamada Y, Getahun H.

Bull World Health Organ. 2018 Mar 1;96(3):173-184F. doi: 10.2471/BLT.17.199414. Epub 2018 Feb 5.

10.

Policies and practices on the programmatic management of LTBI: a survey in the African Region.

Sulis G, Carvalho ACC, Capone S, Hamada Y, Giorgetti PF, da Silva Martins P, Getahun H, Matteelli A.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):158-164. doi: 10.5588/ijtld.17.0563.

PMID:
29506611
11.

Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families.

Getahun H, Matteelli A.

Ann Intern Med. 2017 Nov 21;167(10):742-743. doi: 10.7326/M17-2639. Epub 2017 Nov 7. No abstract available. Erratum in: Ann Intern Med. 2018 Jan 2;168(1):84.

PMID:
29114744
12.

Tuberculosis elimination and the challenge of latent tuberculosis.

Matteelli A, Sulis G, Capone S, D'Ambrosio L, Migliori GB, Getahun H.

Presse Med. 2017 Mar;46(2 Pt 2):e13-e21. doi: 10.1016/j.lpm.2017.01.015. Epub 2017 Mar 6. Review.

PMID:
28279508
13.

Policies and practices on the programmatic management of latent tuberculous infection: global survey.

Hamada Y, Sidibe A, Matteelli A, Dadu A, Aziz MA, Del Granado M, Nishikiori N, Floyd K, Getahun H.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1566-1571.

PMID:
27931330
14.

Assessing the impact of defining a global priority research agenda to address HIV-associated tuberculosis.

Odone A, Matteelli A, Chiesa V, Cella P, Ferrari A, Pezzetti F, Signorelli C, Getahun H.

Trop Med Int Health. 2016 Nov;21(11):1420-1427. doi: 10.1111/tmi.12768. Epub 2016 Aug 31. Review.

15.

The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.

Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D.

Lancet Infect Dis. 2016 Nov;16(11):1269-1278. doi: 10.1016/S1473-3099(16)30216-X. Epub 2016 Aug 10. Review.

PMID:
27522233
16.

Tuberculosis.

Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H, Menzies D, Raviglione M.

Nat Rev Dis Primers. 2016 Oct 27;2:16076. doi: 10.1038/nrdp.2016.76. Review.

PMID:
27784885
17.

Can antiretrovirals curb southern Africa's HIV-associated TB epidemic?

Ford N, Getahun H.

Public Health Action. 2016 Sep;6(3):158-159. Epub 2016 Sep 21. No abstract available.

18.

Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis.

den Boon S, Matteelli A, Getahun H.

Int J Tuberc Lung Dis. 2016 Aug;20(8):1065-71. doi: 10.5588/ijtld.15.0908. Review.

19.

Advancing global programmatic management of latent tuberculosis infection for at risk populations.

Getahun H, Matteelli A, Abubakar I, Hauer B, Pontali E, Migliori GB.

Eur Respir J. 2016 May;47(5):1327-30. doi: 10.1183/13993003.00449-2016. No abstract available.

20.

Tackling the persistent burden of tuberculosis among people living with HIV.

Getahun H, Ford N.

J Int AIDS Soc. 2016 Mar 24;19(1):21002. doi: 10.7448/IAS.19.1.21002. eCollection 2016. No abstract available.

21.

Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration.

Matteelli A, Lönnroth K, Mosca D, Getahun H, Centis R, D'Ambrosio L, Jaramillo E, Migliori GB, Raviglione MC.

Eur Respir J. 2016 Feb;47(2):686-8. doi: 10.1183/13993003.01597-2015. No abstract available.

22.

Service integration to reduce HIV-associated TB mortality.

Ford N, Getahun H.

Public Health Action. 2015 Dec 21;5(4):204. doi: 10.5588/pha.15.0073. No abstract available.

23.

TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis.

Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, Waldrop G, Kranzer K, Doherty M, Getahun H.

J Int AIDS Soc. 2016 Jan 12;19(1):20714. doi: 10.7448/IAS.19.1.20714. eCollection 2016. Review.

24.

Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.

Den Boon S, Matteelli A, Ford N, Getahun H.

AIDS. 2016 Mar 13;30(5):797-801. doi: 10.1097/QAD.0000000000000985. Review.

25.

Model villages: a platform for community-based primary health care.

Admasu K, Balcha T, Getahun H.

Lancet Glob Health. 2016 Feb;4(2):e78-9. doi: 10.1016/S2214-109X(15)00301-0. Epub 2015 Dec 21. No abstract available.

26.

Numbers needed to treat to prevent tuberculosis.

Matteelli A, Lönnroth K, Getahun H, Falzon D, Migliori GB, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1838-9. doi: 10.1183/13993003.01179-2015. No abstract available.

27.

Expanding human immunodeficiency virus testing and counseling to reach tuberculosis clients' partners and families.

Courtenay-Quirk C, Date A, Bachanas P, Baggaley R, Getahun H, Nelson L, Granich R.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1414-6. doi: 10.5588/ijtld.15.0007.

28.

Local innovations and country ownership for sustainable development.

Balcha T, Getahun H, Admasu K.

Bull World Health Organ. 2015 Nov 1;93(11):742. doi: 10.2471/BLT.15.164483. No abstract available.

29.

Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M.

Eur Respir J. 2015 Dec;46(6):1563-76. doi: 10.1183/13993003.01245-2015. Epub 2015 Sep 24. Review.

30.

Latent Mycobacterium tuberculosis Infection.

Getahun H, Chaisson RE, Raviglione M.

N Engl J Med. 2015 Sep 17;373(12):1179-80. doi: 10.1056/NEJMc1508223. No abstract available.

PMID:
26376149
31.

Differences in BCG vaccination and tuberculin skin-test positivity.

Sidibe A, Matteelli A, Menzies R, Getahun H.

Lancet Infect Dis. 2015 Sep;15(9):1003. doi: 10.1016/S1473-3099(15)00233-9. No abstract available.

32.

Latent Mycobacterium tuberculosis infection.

Getahun H, Matteelli A, Chaisson RE, Raviglione M.

N Engl J Med. 2015 May 28;372(22):2127-35. doi: 10.1056/NEJMra1405427. Review. No abstract available.

PMID:
26017823
33.

Transitioning from 'stopping' to 'ending' the tuberculosis epidemic.

Getahun H, Varma J.

Int J Tuberc Lung Dis. 2015 Jun;19(6):623-4. doi: 10.5588/ijtld.15.0307. No abstract available.

34.

WHO's new end TB strategy.

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M; for WHO's Global TB Programme.

Lancet. 2015 May 2;385(9979):1799-1801. doi: 10.1016/S0140-6736(15)60570-0. Epub 2015 Mar 24. No abstract available.

PMID:
25814376
35.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

36.

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion.

Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R, Migliori GB.

Eur Respir J. 2015 Apr;45(4):1170-3. doi: 10.1183/09031936.00216814. Epub 2015 Feb 19. Review. No abstract available.

37.

Provision of antiretroviral therapy for HIV-positive TB patients--19 countries, sub-Saharan Africa, 2009-2013.

Dokubo EK, Baddeley A, Pathmanathan I, Coggin W, Firth J, Getahun H, Kaplan J, Date A.

MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1104-7.

38.

Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.

Churchyard GJ, Chaisson RE, Maartens G, Getahun H.

S Afr Med J. 2014 Apr 16;104(5):339-43. doi: 10.7196/samj.8290. Review.

PMID:
25212199
39.

HIV and multidrug-resistant tuberculosis: overlapping epidemics.

Dean AS, Zignol M, Falzon D, Getahun H, Floyd K.

Eur Respir J. 2014 Jul;44(1):251-4. doi: 10.1183/09031936.00205413. Epub 2014 Feb 13. No abstract available.

40.

Household tuberculosis interventions--how confident are we?

Getahun H, Raviglione M.

Lancet. 2013 Oct 5;382(9899):1157-9. doi: 10.1016/S0140-6736(13)61568-8. Epub 2013 Aug 1. No abstract available.

PMID:
23915880
41.

Managing tuberculosis in people who use and inject illicit drugs.

Getahun H, Baddeley A, Raviglione M.

Bull World Health Organ. 2013 Feb 1;91(2):154-6. doi: 10.2471/BLT.13.117267. No abstract available.

42.

Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review.

Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, Getahun H, Grant AD.

Trop Med Int Health. 2013 Feb;18(2):199-211. doi: 10.1111/tmi.12029. Epub 2012 Dec 10. Review.

43.

PEPFAR support for the scaling up of collaborative TB/HIV activities.

Howard AA, Gasana M, Getahun H, Harries A, Lawn SD, Miller B, Nelson L, Sitienei J, Coggin WL.

J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S136-44. doi: 10.1097/QAI.0b013e31825cfe8e. Review.

44.

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.

Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM.

PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270. Epub 2012 Jul 24. Review.

45.

HIV and tuberculosis--science and implementation to turn the tide and reduce deaths.

Harries AD, Lawn SD, Getahun H, Zachariah R, Havlir DV.

J Int AIDS Soc. 2012;15(2):17396. Review.

46.

Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.

Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R.

AIDS. 2012 Nov 13;26(17):2121-33. doi: 10.1097/QAD.0b013e3283565dd1. Review.

47.

Hurry up and wait? Accelerating access to the Three I's for HIV-TB.

Granich R, Getahun H, Hirnschall G, Raviglione MC.

Int J Tuberc Lung Dis. 2012 Jul;16(7):853-4. doi: 10.5588/ijtld.12.0406. No abstract available.

PMID:
22687495
48.

Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services.

Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M.

Curr Opin HIV AIDS. 2012 Jul;7(4):345-53. doi: 10.1097/COH.0b013e328354bd44. Review.

PMID:
22678489
49.

Community-based multi-disease prevention campaigns for controlling human immunodeficiency virus-associated tuberculosis.

Suthar AB, Klinkenberg E, Ramsay A, Garg N, Bennett R, Towle M, Sitienei J, Smyth C, Daniels C, Baggaley R, Gunneberg C, Williams B, Getahun H, van Gorkom J, Granich RM.

Int J Tuberc Lung Dis. 2012 Apr;16(4):430-6. doi: 10.5588/ijtld.11.0480.

PMID:
22640510
50.

Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A.

Lancet. 2012 May 19;379(9829):1902-13. doi: 10.1016/S0140-6736(12)60727-2. Review. Erratum in: Lancet. 2012 Jun 16;379(9833):2242.

PMID:
22608339

Supplemental Content

Loading ...
Support Center